| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2991 |
| Trial ID | NCT05326243 |
| Disease | Primary Mediastinal B-Cell Lymphoma | Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | PL001 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Pell Bio-Med Technology Co., Ltd. |
| Other ID(s) | PL001-NHL-201 |
| Cohort 1 | |||||||||||
|
|||||||||||